Boston Scientific (NYSE: BSX) announced new study findings demonstrating the superiority of its Farapulse pulsed field ...

Atrial tachyarrhythmia recurred in 39 patients treated with Boston Scientific’s Farapulse PFA device, while 53 people had recurrence in the Medtronic cryoablation group.

The SINGLE SHOT CHAMPION study increases momentum for PFA as a first-line option for pulmonary vein isolation, say experts.

Boston Scientific reported that electrophysiology sales grew 172% in Q4 2024, driven by an uptake of its Farapulse pulsed field ablation (PFA) system. Revealing its Q4 and full-year results ...

Steven Mickelsen, the electrophysiologist who founded Farapulse before it was sold to Boston Scientific in 2021, is taking pulsed field ablation into new territory with the development of a device ...

Abbott is joining the worldwide race to make pulsed field ablation the standard procedure for atrial fibrillation with an ...

Boston Scientific’s BSX robust expansion of operations across different geographies outside the United States is poised to help it grow in the upcoming quarters. The company’s Electrophysiology (EP) ...